AbbieVie Buys ImmunoGen: A Groundbreaking $10.1 Billion Acquisition

103
SHARE

A Vision for Cancer Care: Leaders Speak

Enter Email to View Articles

Loading...

AbbVie’s Richard A. Gonzalez expressed the acquisition as a testament to their commitment to long-term growth and a diversified oncology portfolio. ImmunoGen’s CEO, Mark Enyedy, mirrored this enthusiasm, noting that AbbVie’s global reach and expertise would maximize Elahere’s potential and expedite its expansion.

Financial Advisors: Guiding the Mega-Deal

J.P. Morgan Securities leads the financial advisory for AbbVie, with Morgan Stanley & Co. LLC also playing a key role. On ImmunoGen’s side, Goldman Sachs & Co. and Lazard are providing financial counsel.

The Potential Impact: Transforming Oncology Treatment

Elahere’s success in treating platinum-resistant ovarian cancer, known for its chemotherapy resistance, highlights the potential of ImmunoGen’s oncology portfolio to drive AbbVie’s long-term revenue growth in this sector.

Legal Expertise: Navigating the Acquisition

The legal landscape of this acquisition features a formidable lineup. AbbVie’s representation by Wachtell Lipton includes experts in corporate, finance, litigation, and more, while additional counsel details for ImmunoGen’s representation by Ropes & Gray remain undisclosed.